YS VS THTX Stock Comparison

Performance

YS
10/100

YS returned -94.73% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

THTX
10/100

THTX returned -82.33% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Volatility

YS
23/100

YS has had a lower than average amount of volatility over the last 12 months giving it a score of 22 of 100.

THTX
51/100

THTX has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

Technicals

YS

"Technicals" not found for YS

THTX
50/100

THTX receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

YS

"Earnings" not found for YS

THTX
10/100

THTX has missed earnings 15 times in the last 20 quarters.

Profit

YS

"Profit" not found for YS

THTX
10/100

Out of the last 20 quarters, THTX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

YS Biopharma Co., Ltd. Ordinary Shares Summary

Nasdaq / YS

Healthcare

Biotechnology

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Theratechnologies Inc. Common Summary

Nasdaq / THTX

Healthcare

Drug Manufacturers - Specialty & Generic

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Power up your portfolio